2021 MIPS Measure #462: Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy 

Measure Type High Priority Measure? Collection Type(s)
Process no eCQM


Measure Description

Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater (indicated by HCPCS code) and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT


CMS-Endocrinology-2021, CMS-Oncology-2021, CMS-Urology-2021, General Oncology-2021, Hematology-Oncology, Quality-2021, Urology